Your new post is loading...
Learn about the development of a transgenic rat for the generation of human monoclonal antibodies at OMT.
Open Monoclonal Technology, Inc. ("OMT")
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for discovery of human therapeutic antibodies. It is the only company with three transgenic animal platforms — OmniRat®, OmniMouse®, and OmniFlic™ — collectively known as OmniAb™. All OmniAb platforms have broad freedom to operate, are protected by new patents and patent applications, and are available for all targets and indications.
OmniRat is the first human monoclonal antibody platform to use rats.With its complete immune system and diverse antibody repertoire, OmniRat generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouseis a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability. OmniFlic™ is the first rat engineered with a fixed light chain for discovery of bi-specific, fully human antibodies.
Via Krishan Maggon
OMT makes the OmniAb platforms available directly to partners in a range of flexible and cost-efficient licenses. OmniAb antibody discovery and development services are also available at US-based Antibody Solutions (www.antibodysolutions.com), Europe-based Aldevron (www.aldevron.com), and China-based WuXi AppTec (www.wuxiapptec.com).
OMT was founded in 2007 by the company's CEO, Dr. Roland Buelow, and financed in 2008 by Essex Woodlands Health Ventures, one the largest and most respected healthcare venture companies in the industry. Dr. Buelow previously founded Therapeutic Human Polyclonals (THP) which developed genetically engineered rabbits, partnered with SangStat Medical Corporation (SMC), and sold to Roche in 2007. OMT works with its UK-based affiliate, Recombinant Antibody Technology, Ltd. (RAT) (www.ratltd.net) for genetic engineering.
Big pharma has licensed OMT tech for mabs
Pfizer, Roche, J&j, Merck Serono,